Amgen's Q1 2024 earnings call highlighted robust performance across its therapeutic pillars, with significant sales growth in several key products such as Repatha, EVENITY, and TEZSPIRE. The company's strategic advancements, including the Horizon integration and the promising pipeline developments like MariTide and tarlatamab, were emphasized as drivers of future growth. The anticipated upcoming approvals and clinical trial readouts, along with strategic expansions in manufacturing and geographic markets, signal a strong outlook. However, the ambitious guidance and heavy R&D investment expectations suggest high pressure for continued execution, likely resulting in a positive yet cautiously optimistic market reaction in the short term.

[1]